Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions

J Oral Pathol Med. 2022 Jul;51(6):546-552. doi: 10.1111/jop.13303. Epub 2022 May 20.

Abstract

Background: A major challenge in the management of patients with oral leukoplakia is the difficulty to identify patients at high risk of developing oral squamous cell carcinoma. Our knowledge about genomic alterations in oral leukoplakia, and in particular those that progress to oral squamous cell carcinoma, is scarce and there are no useful biomarkers that can predict the risk of malignant transformation.

Methods: Using a novel, custom-made tissue microarray including 28 high-risk oral leukoplakias and the corresponding oral squamous cell carcinomas from 14 cases that progressed to cancer, we assayed copy number alterations involving the oral squamous cell carcinoma driver genes CDKN2A, CCND1, EGFR, and MYC by fluorescence in situ hybridization. The copy number alterationss were correlated with clinicopathological data from all patients.

Results: Copy number alterations were identified in 14/24 oral leukoplakias, analyzable for one or more of the oral squamous cell carcinoma driver genes. EGFR was the most frequently altered gene in oral leukoplakias with amplification/gain in 43.5% followed by loss of CDKN2A (26.1%), gains of CCND1 (26.1%), and MYC (8.3%). Losses of CDKN2A were more common in oral leukoplakias progressing to oral squamous cell carcinoma compared to those that did not. Copy number alterations were more common in oral squamous cell carcinomas than in oral leukoplakias.

Conclusions: Our findings demonstrate that copy number alterations involving the oral squamous cell carcinoma drivers CDKN2A, EGFR, and CCND1 occur in oral leukoplakias and suggest a possible role for these genes in the development and/or progression of subsets of oral leukoplakias.

Keywords: CDKN2A; EGFR; fluorescence in situ hybridization; malignant transformation; oral leukoplakia.

MeSH terms

  • Cyclin D1* / genetics
  • Cyclin-Dependent Kinase Inhibitor p16* / genetics
  • DNA Copy Number Variations*
  • Disease Progression
  • ErbB Receptors* / genetics
  • Humans
  • In Situ Hybridization, Fluorescence
  • Leukoplakia, Oral* / genetics
  • Leukoplakia, Oral* / pathology
  • Mouth Neoplasms* / genetics
  • Mouth Neoplasms* / pathology
  • Squamous Cell Carcinoma of Head and Neck* / genetics

Substances

  • CCND1 protein, human
  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Cyclin D1
  • EGFR protein, human
  • ErbB Receptors